Use of biologics in SLE: a review of the evidence from a clinical perspective

被引：10

作者：

Aytan, Jayoti ^{[1
]}

Bukhari, Marwan A. S. ^{[1
,2
]}

机构：

[1] Univ Lancaster, Fac Hlth & Med, Lancaster, England

[2] Univ Hosp Morecambe Bay NHS Fdn Trust, Royal Lancaster Infirm, Dept Rheumatol, Ashton Rd, Lancaster LA1 4RP, England

来源：

RHEUMATOLOGY | 2016年 / 55卷 / 05期

关键词：

lupus; biologics; review; SYSTEMIC-LUPUS-ERYTHEMATOSUS; B-LYMPHOCYTE STIMULATOR; DOUBLE-BLIND; DISEASE-ACTIVITY; MONOCLONAL-ANTIBODY; RITUXIMAB; SAFETY; EFFICACY; NEPHRITIS; BELIMUMAB;

D O I：

10.1093/rheumatology/kev346

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

With the explosion in biologics use in rheumatology, newer and smarter ways of using these drugs in different diseases have been advocated. SLE has to date been at the back of the biologics algorithms. Recently, the US Food and Drug Administration and European Medicines Evaluation Agency licensed belimumab for use in SLE, the first drug in > 30 years. A clinical review of the evidence that underlies the use of belimumab and other biologics in SLE reveals possible reasons why the results are not as spectacular as they are in other diseases.

引用

页码：775 / 779

页数：5

共 42 条

[1]

Andreoli L, 2014, ISR MED ASSOC J, V16, P651

[2] 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis [J].

Braun, J. ;

van den Berg, R. ;

Baraliakos, X. ;

Boehm, H. ;

Burgos-Vargas, R. ;

Collantes-Estevez, E. ;

Dagfinrud, H. ;

Dijkmans, B. ;

Dougados, M. ;

Emery, P. ;

Geher, P. ;

Hammoudeh, M. ;

Inman, R. D. ;

Jongkees, M. ;

Khan, M. A. ;

Kiltz, U. ;

Kvien, T. K. ;

Leirisalo-Repo, M. ;

Maksymowych, W. P. ;

Olivieri, I. ;

Pavelka, K. ;

Sieper, J. ;

Stanislawska-Biernat, E. ;

Wendling, D. ;

Ozgocmen, S. ;

van Drogen, C. ;

van Royen, B. J. ;

van der Heijde, D. .

ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (06) :896-904

[3] Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids [J].

Condon, Marie B. ;

Ashby, Damien ;

Pepper, Ruth J. ;

Cook, H. Terence ;

Levy, Jeremy B. ;

Griffith, Megan ;

Cairns, Tom D. ;

Lightstone, Liz .

ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (08) :1280-1286

[4] Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis [J].

Davies, R. J. ;

Sangle, S. R. ;

Jordan, N. P. ;

Aslam, L. ;

Lewis, M. J. ;

Wedgwood, R. ;

D'Cruz, D. P. .

LUPUS, 2013, 22 (06) :574-582

[5] Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts [J].

Diaz-Lagares, Candido ;

Croca, Sara ;

Sangle, Shirish ;

Vital, Edward M. ;

Catapano, Fausta ;

Martinez-Berriotxoa, Agustin ;

Garcia-Hernandez, Francisco ;

Callejas-Rubio, Jose-Luis ;

Rascon, Javier ;

D'Cruz, David ;

Jayne, David ;

Ruiz-Irastorza, Guillermo ;

Emery, Paul ;

Isenberg, David ;

Ramos-Casals, Manuel ;

Khamashta, Munther A. .

AUTOIMMUNITY REVIEWS, 2012, 11 (05) :357-364

[6]

European Medicines Agency, EMEAHC002015 EUR MED

[7] Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen [J].

Ezeonyeji, Amara N. ;

Isenberg, David A. .

RHEUMATOLOGY, 2012, 51 (03) :476-481

[8] Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study [J].

Fernandez-Nebro, A. ;

Marenco de la Fuente, J. L. ;

Carreno, L. ;

Galindo Izquierdo, M. ;

Tomero, E. ;

Rua-Figueroa, I. ;

Hernandez-Cruz, B. E. ;

Narvaez, J. ;

Ucar, E. ;

Olive, A. ;

Zea, A. ;

Fernandez-Castro, M. ;

Raya-Alvarez, E. ;

Pego-Reigosa, J. M. ;

Freire, M. ;

Martinez-Taboada, V. M. ;

Perez-Venegas, J. ;

Sanchez-Atrio, A. I. ;

Villa-Blanco, I. ;

Manrique-Arija, S. ;

Lopez-Longo, F. J. ;

Carreira, P. E. ;

Martinez-Perez, R. ;

Garcia-Vicuna, R. .

LUPUS, 2012, 21 (10) :1063-1076

[9] Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus [J].

Furie, Richard ;

Stohl, William ;

Ginzler, Ellen M. ;

Becker, Michael ;

Mishra, Nilamadhab ;

Chatham, Winn ;

Merrill, Joan T. ;

Weinstein, Arthur ;

McCune, W. Joseph ;

Zhong, John ;

Cai, Wendy ;

Freimuth, William .

ARTHRITIS RESEARCH & THERAPY, 2008, 10 (05)

[10] Efficacy and Safety of Abatacept in Lupus Nephritis A Twelve-Month, Randomized, Double-Blind Study [J].

Furie, Richard ;

Nicholls, Kathy ;

Cheng, Tien-Tsai ;

Houssiau, Frederic ;

Burgos-Vargas, Ruben ;

Chen, Shun-Le ;

Hillson, Jan L. ;

Meadows-Shropshire, Stephanie ;

Kinaszczuk, Michael ;

Merrill, Joan T. .

ARTHRITIS & RHEUMATOLOGY, 2014, 66 (02) :379-389

← 1 2 3 4 5 →